Authors reply: ‘Response to the British Menopause society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology position statement – Best practice recommendations for the care of women experiencing the menopause’
Authors:
- 14 November 2022
- journal article
- letter
- Published by Taylor & Francis in Post Reproductive Health
- Vol. 28 (4) , 254-258
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidenceThe Lancet, 2019
- Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control studyBMJ, 2019
- The British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiencyPost Reproductive Health, 2017
- Reduced risk of breast cancer mortality in women using postmenopausal hormone therapy: a Finnish nationwide comparative studyMenopause, 2016
- 2016 IMS Recommendations on women’s midlife health and menopause hormone therapyClimacteric, 2016
- Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective StudyPLOS Medicine, 2015
- Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trialEuropean Journal of Cancer, 2013
- Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trialThe Lancet Oncology, 2009
- HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stoppedThe Lancet, 2004
- Effect of Estrogen Plus Progestin on Global Cognitive Function in Postmenopausal WomenJAMA, 2003